Insulin degludec

• Main Authors: Vishakha V Jain, Omprakash Gupta
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2013-01-01
• Series: Journal of Mahatma Gandhi Institute of Medical Sciences
• Subjects: Basal insulin; insulin analogues; insulin degludec
• Online Access: http://www.jmgims.co.in/article.asp?issn=0971-9903;year=2013;volume=18;issue=2;spage=103;epage=108;aulast=Jain

Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a flat, stable glucose-lowering effect in patients with type 1 or type 2 diabetes mellitus. Findings from clinical trials have demonstrated that new-generation, once-daily basal insulin degludec provides similar A1C control as compared to insulin glargine, both administered as basal-oral therapy or in combination with insulin aspart, with the added benefits of lower rates of hypoglycemia, particularly nocturnal hypoglycemia.